Daily1 小时
JnJ Nipocalimab gets USFDA Priority Review designation for generalized myasthenia gravis
House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review ...
PipelineReview.com20 小时
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with ...
NEW YORK, NY. USA I January 10, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating ...
Armed robbery in Revesby23 小时
Pfizer's Sasanlimab Boosts Survival in Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...
tbsnews5 小时
Why all the buzz about inflammation — and just how bad is it?
Inflammation often gets a bad reputation, frequently linked to deadly conditions like heart disease, stroke, dementia, and cancer. But is inflammation the enemy it's made out to be? Let's break it ...
Le Lézard19 小时
Immunis Closes $25 Million Series A-1 Financing Round
Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million Series A-1 financing round to fund two Phase 2 ...